WuXi Completed First GMP Production at New 24,000L Line of MFG5 Facility
WuXi Biologics, a global company with leading open-access biologics technology platforms has recently announced that the first GMP production at the new 24,000L line of its drug substance facility MFG5 has successfully completed. This new line in addition to the 36,000L biomanufacturing line of MFD5 makes the total production capacity to 60,000L. MFG5 aims to further support the demand of manufacture of late-phase and commercial projects across multiple modalities, such as monoclonal antibodies, bispecifics and fusion proteins.
The new 24,000L line combines bioreactors with various production processes including fed-batch, perfusion and CFB of twelve single-use bioreactors of sizes ranging from 2,000L to 12,000L. Also, with the implementation of WuXiUP™ continuous downstream technology in the 24,000L line, it is expected to increase productivity and reduce Cost of Goods Sold (COGS) of MFG5.
Dr. Chris Chen, CEO of WuXi Biologics mentioned that, MFG5 has comparable cost structure as any current largest biologics facilities running up to 25,000L scale as one of the largest cGMP biologics manufacturing facilities in the world to employ only single-use bioreactors.